medigraphic.com
ISSN 0016-3813 (Print)

2004, Number S3

<< Back Next >>

Gac Med Mex 2004; 140 (S3)

SELECT TOPICS IN MEDICINE TRANSFUSIONAL

II. Pharmacological alternatives of the transfusion

Radillo-González A

Language: Spanish
References: 34
Page: 152-156
PDF size: 46.28 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lichtiger B. Futuro de la medicina transfusional en el siglo XXI. En Radillo GA. Medicina Transfusional. México: Ed. Prado, S.A. de C.V. 1999: 635-642.

  2. Radillo GA. Actualidades en medicina transfusional uso de los componentes sanguíneos: eritrocitos, leucocitos, plasma, plaquetas y crioprecipitados. Bioquímica 2004; 29: 65-67.

  3. Radillo GA. Sustitutos de los eritrocitos. En Radillo GA. Medicina Transfusional. México: Ed. Prado, S.A. de C.V. 1999: 623-633.

  4. Widan FK. Accept no substitute. Lancet 1997; 350 (Supl.III): 27

  5. Hess JR, Reis RF. Resuscitation an the limited utility of the present generation of blood substitutes. Transfusion Med Rev 1996; X4: 276-285.

  6. Olding-Smee W. Sustitutos de glóbulos rojos. En Contreras M. ABC de la transfusión Chile 2da. Ed. Mediterráneo 1992; 57-59.

  7. Jones JA. Red blood cell substitutes: current status. Br. J Anaesthesia 1995; 74: 697-703.

  8. Standl TG, et al. Haemodynamic changes and skeletal muscle oxygen tension during complete blood exchange with ultrapurified polymerized bovine haemoglobin. Intensive Car Med 1997; 23: 865-872.

  9. Standl TG, et al. Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection. Br J Anaesthesia 1998; 80: 189-194.

  10. Dyer O. Desarrollo de sangre artificial con ayuda de cocodrilos. BMJ 1995; 3: 108-109.

  11. Komiyama N, Tame J, Nakai K. A hemoglobin-based blood substitute: transplanting a novel allosteric effect of crocodile Hb. Biol Chem. 1996; 377(9): 543-548.

  12. Taylor MJ et al. A new solution for life without blood asanguineous low-flow perfusion of a whole-body perfusate during 3 hours of cardiac arrest and profound hypothermia. Circulation 1995; 91(2): 341-344.

  13. Ness P. Pharmacologic alternatives to transfusion. Vox Sanguinis 2002; 83 (Suppl 1:3-6.

  14. Michiels J, et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Seminars in Thrombosis and Hemostasis 2002; 28: 113-131.

  15. Newby DE, et al. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6. Thromb. Haemost. 2000; 84: 195-203.

  16. Sadler JE, Mannuci PM, Berntorp E, Bochkoy N, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000; 84: 160-174.

  17. Tobias J. Strategies for minimizing blood loss in orthopedic surgery. Seminars in Hematology, 2004; 41 (Suppl 1): 145-146.

  18. Dene C, Noble S. Aprotinin. An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999; 57: 1-26.

  19. Scheule AM, Beierlein W, Arnold S, et al. The significance of preformed aprotinina-specific antibodies in cardiosurgical patients. Anesth Analg 2000; 90:262-266.

  20. Kessler CM. Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Seminars in Hematology 2004; 41 (Suppl.1): 44-50.

  21. Abshire T. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Seminars in Hematology 2004; 41 (Suppl 1): 3-7.

  22. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Seminars in Hematology 2004; 41 (Suppl.1): 35-39.

  23. Kovesti T, and Royston D. Pharmacological approaches to reducing allogenic blood exposure. Vox Sanguinis 2003; 84: 2-10.

  24. Sallah A, Wan J, et al. Recombinant activated factor VII can control the bleeding manifestations of disseminated intravascular coagulation in patients with cancer. Abs. Blood 2002; 100-11:3873.

  25. Tamponi G, Schinco P, et al. Alternative treatment with rVIIa for dental extraction in one outpatient with Glanzmann Thromboasthenia. Abs. Blood 2002; 100-11: 3887.

  26. Yildirim Z. Branda R, et al. Use of recombinant activate factor VII (rFVIIa) to correct coagulopathy due to congestive liver failure in preparation for surgery. Abs. Blood 2002; 100-11:3888.

  27. Strauss RA, Gloster ES, et al. Off-label use of recombinant activate factor VII (rFVIIa) for enucleation following eye trauma. Abs. Blood 2002; 100-11: 3910.

  28. Goodnough L. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Seminars in Hematology 2004; 41 (Suppl.1):25-29.

  29. Levi M, Bijsterveld NR, and Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in Hematology 2004; 41 (Suppl.1): 65-69.

  30. O’Connell N. Factor XI deficiency. Seminars in Hematology 2004; 41 (Suppl.1):76-81.

  31. Alving B. Platelet substitutes: the reality and the potential. Vox Sanguinis 2002; 83 (Suppl.1): 287-288.

  32. Roberts H, Monroe III D and Hoffman M. Safety profile of recombinant factor VIIa. Seminars in Hematology 2004; 41 (Suppl.1): 101-108.

  33. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. Journal of Thrombosis and Haemostasis 2003; 1: 1637-1641.

  34. Furie B. Déficit de vitamina K. En Rakel R. Conn Terapéutica actual. Madrid. McGraw-Hill-Interamericana de España 1993;606-608.




2020     |     www.medigraphic.com